Pyxis Oncology (PYXS) Current Deferred Revenue (2023)
Pyxis Oncology (PYXS) reported Current Deferred Revenue of $7.7 million for Q4 2023, up 6.55% quarter-over-quarter from $7.2 million in Q3 2023.
Pyxis Oncology (PYXS) Current Deferred Revenue (2023) Analysis & Trends
Pyxis Oncology (PYXS) has 1 years of Current Deferred Revenue data on file, last reported at $7.7 million in Q4 2023.
- Current Deferred Revenue for Q4 2023 came in at $7.7 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $7.7 million (changed N/A YoY), and the FY2023 annual result was $7.7 million, changed N/A from the prior year.
- Current Deferred Revenue climbed to $7.7 million in Q4 2023 per PYXS's latest filing, from $7.2 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $7.7 million in Q4 2023 and troughed at $7.2 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 7.66 Mn |
| Sep 30, 2023 | 7.19 Mn |